Antiplatelet Therapy for Every Diabetic Person?
نویسندگان
چکیده
منابع مشابه
Antiplatelet Therapy for Every Diabetic Person?
Until recently, aspirin was recommended by most guidelines for the primary prevention of cardiovascular events in people with diabetes. Recommendations were primarily based on indirect evidence from large trials of populations at high risk of cardiovascular (CV) events. Evidence supporting the efficacy of aspirin therapy in trials of diabetic subjects only is scant. A previous meta-analysis on ...
متن کاملDrug-eluting stents: dual antiplatelet therapy for every survivor?
No recent pharmaceutical or medical device has generated as much ongoing and expanding attention as drug-eluting stents (DES). In fact there has been an explosion of published reports on the topic within cardiology, medical, surgical and subspecialty journals. The device industry has repeatedly sent their own summaries of information directly to physicians, while mainstream media has kept the c...
متن کاملAntiplatelet Therapy – Recent Advances
Haemostatic function of platelets is vital & their pathological role is potentially lethal. In pathological states there is over activation and aggregation of blood platelets resulting in atherothrombosis causes various states from angina to acute coronary syndromes, stroke and peripheral artery diseases. Platelets are anuclear subcellular fragments derived from megakaryocytes that circulate in...
متن کاملPerioperative antiplatelet therapy.
Aspirin is recommended as a lifelong therapy that should never be interrupted for patients with cardiovascular dis- ease. Clopidogrel therapy is mandatory for six weeks after placement of bare-metal stents, three to six months after myocardial infarction, and at least 12 months after placement of drug-eluting stents. Because of the hypercoagulable state induced by surgery, early withdrawal of a...
متن کاملEditorial: Antiplatelet Therapy for Mitral Stenosis?
IN THIS ISSUE of Circulation, Steele and Rainwater report the results of a clinical trial of sulfinpyrazone to reduce systemic thromboemboli in patients with mitral stenosis.' Each patient was studied for 4 years, with careful monitoring of clinical events and repeated measurements of platelet survival. Their results indicate that sulfinpyrazone is effective in reducing the incidence of thrombo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Diabetes Care
سال: 2011
ISSN: 0149-5992,1935-5548
DOI: 10.2337/dc11-s210